OBJECTIVE: While bone marrow edema (BME) detected by magnetic resonance imaging (MRI) is a biomarker of arthritis, its nature remains poorly understood due to the limitations of clinical studies. In this study, MRI of murine arthritis was used to elucidate its cellular composition and vascular involvement. METHODS: BME was quantified using normalized bone marrow intensity (NBMI) from precontrast MRI and normalized marrow contrast enhancement (NMCE) following intravenous administration of gadopentate dimeglumine. Wild-type (WT) and tumor necrosis factor (TNF)-transgenic mice were scanned from 2 to 5 months of age, followed by histologic or fluorescence-activated cell sorting (FACS) analysis of marrow. In efficacy studies, TNF-transgenic mice were treated with anti-TNF or placebo for 8 weeks, and then were studied using bimonthly MRI and histologic analysis. RESULTS: NBMI values were similar in WT and TNF-transgenic mice at 2 months. The values in WT mice steadily decreased thereafter, with mean values becoming significantly different from those of TNF-transgenic mice at 3.5 months (mean +/- SD 0.29 +/- 0.08 versus 0.46 +/- 0.13; P < 0.05). Red to yellow marrow transformation occurred in WT but not TNF-transgenic mice, as observed histologically at 5 months. The marrow of TNF-transgenic mice that received anti-TNF therapy converted to yellow marrow, with lower NBMI values versus placebo at 6 weeks (mean +/- SD 0.26 +/- 0.07 versus 0.61 +/- 0.22; P < 0.05). FACS analysis of bone marrow revealed a significant correlation between NBMI values and CD11b+ monocytes (R2 = 0.91, P = 0.0028). Thresholds for "normal" red marrow versus pathologic BME were established, and it was also found that inflammatory marrow is highly permeable to contrast agent. CONCLUSION: BME signals in TNF-transgenic mice are caused by yellow to red marrow conversion, with increased myelopoiesis and increased marrow permeability. The factors that mediate these changes warrant further investigation.
OBJECTIVE: While bone marrow edema (BME) detected by magnetic resonance imaging (MRI) is a biomarker of arthritis, its nature remains poorly understood due to the limitations of clinical studies. In this study, MRI of murinearthritis was used to elucidate its cellular composition and vascular involvement. METHODS: BME was quantified using normalized bone marrow intensity (NBMI) from precontrast MRI and normalized marrow contrast enhancement (NMCE) following intravenous administration of gadopentate dimeglumine. Wild-type (WT) and tumor necrosis factor (TNF)-transgenic mice were scanned from 2 to 5 months of age, followed by histologic or fluorescence-activated cell sorting (FACS) analysis of marrow. In efficacy studies, TNF-transgenic mice were treated with anti-TNF or placebo for 8 weeks, and then were studied using bimonthly MRI and histologic analysis. RESULTS:NBMI values were similar in WT and TNF-transgenic mice at 2 months. The values in WT mice steadily decreased thereafter, with mean values becoming significantly different from those of TNF-transgenic mice at 3.5 months (mean +/- SD 0.29 +/- 0.08 versus 0.46 +/- 0.13; P < 0.05). Red to yellow marrow transformation occurred in WT but not TNF-transgenic mice, as observed histologically at 5 months. The marrow of TNF-transgenic mice that received anti-TNF therapy converted to yellow marrow, with lower NBMI values versus placebo at 6 weeks (mean +/- SD 0.26 +/- 0.07 versus 0.61 +/- 0.22; P < 0.05). FACS analysis of bone marrow revealed a significant correlation between NBMI values and CD11b+ monocytes (R2 = 0.91, P = 0.0028). Thresholds for "normal" red marrow versus pathologic BME were established, and it was also found that inflammatory marrow is highly permeable to contrast agent. CONCLUSION: BME signals in TNF-transgenic mice are caused by yellow to red marrow conversion, with increased myelopoiesis and increased marrow permeability. The factors that mediate these changes warrant further investigation.
Authors: Fiona M McQueen; Nick Benton; David Perry; Jeff Crabbe; Elizabeth Robinson; Sue Yeoman; Lachy McLean; Neal Stewart Journal: Arthritis Rheum Date: 2003-07
Authors: Mikkel Østergaard; Charles Peterfy; Philip Conaghan; Fiona McQueen; Paul Bird; Bo Ejbjerg; Ron Shnier; Philip O'Connor; Mette Klarlund; Paul Emery; Harry Genant; Marissa Lassere; John Edmonds Journal: J Rheumatol Date: 2003-06 Impact factor: 4.666
Authors: Christopher T Ritchlin; Sally A Haas-Smith; Ping Li; David G Hicks; Edward M Schwarz Journal: J Clin Invest Date: 2003-03 Impact factor: 14.808
Authors: Lisa M Flick; Jason M Weaver; Michael Ulrich-Vinther; Faruk Abuzzahab; Xinping Zhang; William C Dougall; Dirk Anderson; Regis J O'Keefe; Edward M Schwarz Journal: J Orthop Res Date: 2003-07 Impact factor: 3.494
Authors: David J Shealy; Paul H Wooley; Eva Emmell; Amy Volk; Amy Rosenberg; George Treacy; Carrie L Wagner; Lois Mayton; Don E Griswold; Xiao-Yu R Song Journal: Arthritis Res Date: 2002-06-28
Authors: Amr Alaarg; Carlos Pérez-Medina; Josbert M Metselaar; Matthias Nahrendorf; Zahi A Fayad; Gert Storm; Willem J M Mulder Journal: Adv Drug Deliv Rev Date: 2017-05-12 Impact factor: 15.470
Authors: Jie Li; Igor Kuzin; Safiehkhatoon Moshkani; Steven T Proulx; Lianping Xing; Denise Skrombolas; Robert Dunn; Iñaki Sanz; Edward M Schwarz; Andrea Bottaro Journal: J Immunol Date: 2010-04-30 Impact factor: 5.422
Authors: A Mitra; S Kundu-Raychaudhuri; C Abria; A Rona; A J Chaudhari; S P Raychaudhuri Journal: Clin Exp Immunol Date: 2017-02-24 Impact factor: 4.330
Authors: M Owen Papuga; Edmund Kwok; Zhigang You; Paul T Rubery; Paul E Dougherty; Gloria Pryhuber; Christopher A Beck; Matthew J Hilton; Hani A Awad; Edward M Schwarz Journal: J Orthop Res Date: 2011-03-28 Impact factor: 3.494
Authors: Echoe M Bouta; Richard D Bell; Homaira Rahimi; Lianping Xing; Ronald W Wood; Clifton O Bingham; Christopher T Ritchlin; Edward M Schwarz Journal: Nat Rev Rheumatol Date: 2018-01-11 Impact factor: 20.543
Authors: M Owen Papuga; Steven T Proulx; Edmund Kwok; Zhigang You; Paul T Rubery; Paul E Dougherty; Matthew J Hilton; Hani A Awad; Edward M Schwarz Journal: J Orthop Res Date: 2010-09 Impact factor: 3.494
Authors: Edward M Schwarz; Steven T Proulx; Christopher T Ritchlin; Brendan F Boyce; Lianping Xing Journal: Adv Exp Med Biol Date: 2010 Impact factor: 2.622
Authors: Echoe M Bouta; Ronald W Wood; Edward B Brown; Homaira Rahimi; Christopher T Ritchlin; Edward M Schwarz Journal: J Physiol Date: 2014-01-13 Impact factor: 5.182
Authors: Jie Li; Yawen Ju; Echoe M Bouta; Lianping Xing; Ronald W Wood; Igor Kuzin; Andrea Bottaro; Christopher T Ritchlin; Edward M Schwarz Journal: Arthritis Rheum Date: 2013-01